التفاصيل البيبلوغرافية
| العنوان: |
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. |
| المؤلفون: |
Gilreath, Jeffrey A., Wei, Mei, Paul, Shilpa, Parker, Charles J., Stenehjem, David D., Rodgers, George M. |
| المصدر: |
Journal of Oncology Pharmacy Practice; Apr2019, Vol. 25 Issue 3, p719-723, 5p, 1 Graph |
| مصطلحات موضوعية: |
THROMBOPENIC purpura diagnosis, CELL receptors, DRUG monitoring, PLATELET count, RECOMBINANT proteins, THERAPEUTICS |
| مستخلص: |
Romiplostim is a thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia purpura. When following FDA-approved romiplostim prescribing recommendations to withhold treatment for platelet counts above 400k/µL, some patients exhibit a precipitous decline in their platelet count potentially causing patient harm. We present two cases where stable platelet counts were achieved only through persistent weekly dosing of romiplostim despite platelet counts above 400k/µL on the day of administration. Therefore, continuous weekly dosing of romiplostim despite platelet count being above 400k/µL combined with twice weekly vigilant monitoring is an alternative method of romiplostim dosing that mitigates severe fluctuations in platelets. We also discuss important details, postulated mechanisms, and evidence-based mitigation strategies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Oncology Pharmacy Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
